Japan Approves Shionogi Allergy Drug For Helping Unborns Breathe
This article was originally published in PharmAsia News
Executive Summary
Japan's health ministry agreed to cover Shionogi's betamethasone under the nation's health-insurance system. The drug has been sold in Japan since the 1960s, but only for treatment of allergies. The newly approved indication is for unborn babies to help them breathe. The approval marks the first in Japan for a treatment aimed at the not-yet-born. Shionogi markets the drug in Japan as Rinderon. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.